参考文献/References:
[1] Kwon SH,Shin JP,Kim IT,et al.Association of plasma semaphorin 3A with phenotypes of diabetic retinopathy and nephropathy[J].Invest Ophthalmol Vis Sci,2016,57(7):2983-2989.DOI:10.1167/iovs.16-19468.
[2] Rezaeepoor M,Shapoori S,Ganjalikhani-Hakemi M,et al. Decreased expression of Sema3A, an immune modulator, in blood sample of multiple sclerosis patients[J].Gene,2017,610:59-63.DOI:10.1016/j.gene.2017.02.013.
[3] Noguchi K,Ishikawa R,Kawaguchi M,et al.Expression patterns of Sema3A in developing amniote limbs: with reference to the diversification of peripheral nerve innervation[J].Dev Growth Differ,2017,59(4):270-285.DOI:10.1111/dgd.12364.
[4] Ma R,Wang L,Zhao B,et al.Diabetes perturbs bone microarchitecture and bone strength through regulation of Sema3A/IGF-1/β-catenin in rats[J].Cell Physiol Biochem,2017,41(1):55-66.DOI:10.1159/000455936.
[5] Zhao C,Liu J,Zhang M,et al.Semaphorin 3A deficiency improves hypoxia-induced myocardial injury via resisting inflammation and cardiomyocytes apoptosis[J].Cell Mol Biol(Noisy-le-grand),2016,62(2):8-14.
[6] Merte J,Wang Q,Vander Kooi CW,et al.A forward genetic screen in mice identifies Sema3A(K108N), which binds to neuropilin-1 but cannot signal[J].J Neurosci,2010, 30(16):5767-5775.DOI:10.1523/JNEUROSCI.5061-09.2010.
[7] Nogi T,Yasui N,Mihara E,et al. Structural basis for semaphorin signalling through the plexin receptor[J].Nature,2010,467(7319):1123-1127.DOI:10.1038/nature09473.
[8] Kigel B,Rabinowicz N,Varshavsky A,et al.Plexin-A4 promotes tumor progression and tumor angiogenesis by enhancement of VEGF and bFGF signaling[J].Blood,2011,118(15):4285-4296.DOI:10.1182/blood-2011-03-341388.
[9] Reidy KJ,Aggarwal PK,Jimenez JJ,et al. Excess podocyte semaphorin-3A leads to glomerular disease involving plexinA1-nephrin interaction[J].Am J Pathol,2013,183(4):1156-1168.DOI:10.1016/j.ajpath.2013.06.022.
[10] Aggarwal PK,Veron D,Thomas DB,et al.Semaphorin3a promotes advanced diabetic nephropathy[J].Diabetes,2015,64(5):1743-1759.DOI:10.2337/db14-0719.
[11] Veron D,Bertuccio CA,Marlier A,et al.Podocyte vascular endothelial growth factor(Vegf164)overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes[J].Diabetologia,2011,54(5):1227-1241.DOI:10.1007/s00125-010-2034-z.
[12] Rodriguez F,Lopez B,Perez C,et al. Chronic tempol treatment attenuates the renal hemodynamic effects induced by a hemeoxygenase inhibitor in streptozotocin diabetic rats[J].Am J Physiol Regul Integr Comp Physiol,2011,301(5):R1540-R1548.DOI:10.1152/ajpregu.00847.2010.
[13] Saad S,Dharmapatni AASSK,Crotti TN,et al.Semaphorin-3a, neuropilin-1 and plexin-A1 in prosthetic-particle induced bone loss[J].Acta Biomater,2016,30:311-318.DOI:10.1016/j.actbio.2015.11.025.
[14] Sakai T,Takahashi D,Nikaido K,et al.Co-stimulation with interleukin-4 and tumor necrosis factor-α increases epidermalinnervation accompanied by suppression of semaphorin 3A[J].J Dermatol Sci,2014,76(1):69-71.DOI:10.1016/j.jdermsci.2014.06.005.
[15] 阳石坤,肖力,刘伏友,等.cAMP-Epac-Rap1信号通路在肾脏疾病中的研究进展 [J]. 中华肾脏病杂志,2012,28(6): 498-501. DOI:10.3760/cma.j.issn.1001-7097.2012.06.018.
[16] Cheema HR,Al Habash A,Al-Askar E.Improvement of visual acuity based on optical coherence tomography patterns following intravitreal bevacizumab treatment in patients with diabetic macular edema[J].Int J Ophthalmol,2014,7(2):251-255.DOI:10.3980/j.issn.2222-3959.2014.02.11.
[17] Wang J,Wang S,Li M,et al.The neuropilin-1 inhibitor, ATWLPPR peptide, prevents experimental diabetes-induced retinal Injury by preserving vascular integrity and decreasing oxidative stress[J].PLoS One,2015,10(11):e0142571.DOI:10.1371/journal.pone.0142571.
[18] Groppa E,Brkic S,Bovo E,et al..VEGF dose regulates vascular stabilization through Semaphorin3A and the Neuropilin-1+ monocyte/TGF-β1 paracrine axis[J].EMBO Mol Med,2015,7(10):1366-1384.DOI:10.15252/emmm.201405003.
[19] Acevedo LM,Barillas S,Weis SM,et al.Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor[J].Blood,2008,111(5):2674-2680.DOI:10.1182/blood-2007-08-110205.
[20] Hou ST, Nilchi L, Li X,et al.Semaphorin3A elevates vascular permeability and contributes to cerebral ischemia-induced brain damage[J].Sci Rep,2015,5:7890. DOI:10.1038/srep07890. DOI:10.1038/srep07890.
[21] Cerani A,Tetreault N,Menard C,et al.Neuron-derived semaphorin 3A is an early inducer of vascular permeability in diabetic retinopathy via neuropilin-1[J].Cell Metab,2013,18(4):505-518. DOI:10.1016/j.cmet.2013.09.003.
[22] Li G,Veenstra AA,Talahalli RR,et al.Marrow-derived cells regulate the development of early diabetic retinopathy and tactile allodynia in mice[J].Diabetes,2012,61(12):3294-3303.DOI:10.2337/db11-1249.
[23] Huang X,Sun M,Li D,et al.Augmented NADPH oxidase activity and p22phox expression in monocytes underlie oxidative stress of patients with type 2 diabetes mellitus[J].Diabetes Res Clin Pract,2011,91(3):371-380.DOI:10.1016/j.diabres.2010.12.026.
[24] Tanaka J,Tanaka H,Mizuki N,et al.Semaphorin 3A controls allergic and inflammatory responses in experimental allergic conjunctivitis[J].Int J Ophthalmol,2015,8(1):1-10. DOI:10.3980/j.issn.2222-3959.2015.01.01.
[25] Ang L,Jaiswal M,Martin C,et al.Glucose control and diabetic neuropathy: lessons from recent large clinical trials[J].Curr Diab Rep,2014,14(9):528.DOI:10.1007/s11892-014-0528-7.
[26] Pop-Busui R,Ang L,Holmes C,et al.Inflammation as a therapeutic target for diabetic neuropathies[J].Curr Diab Rep,2016,16(3):29.DOI:10.1007/s11892-016-0727-5.
相似文献/References:
[1]李春睿,王静,陈峰,等.GLP-1受体激动剂对糖尿病患者肾功能的影响[J].国际内分泌代谢杂志,2014,(06):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
Li Chunrui*,Wang Jing,Chen Feng,et al.Effects of GLP-1 receptor agonists on renal function of diabetics[J].International Journal of Endocrinology and Metabolism,2014,(01):401.[doi:10.3760/cma.j.issn.1673-4157.2014.06.011]
[2]黄珊珊,鲁一兵.长链非编码RNA与糖尿病[J].国际内分泌代谢杂志,2015,(04):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
Huang Shanshan*,Lu Yibing..Long non-coding RNA and diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(01):271.[doi:10.3760/cma.j.issn.1673-4157.2015.04.016]
[3]高瑞霄,姚朱华,冯凭,等.尿8-羟基脱氧鸟苷在2型糖尿病及糖尿病合并冠心病患者中的临床意义[J].国际内分泌代谢杂志,2014,(05):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
Gao Ruixiao*,Yao Zhuhua,Feng Ping,et al.The clinical significance of urinary 8-hydroxy deoxyguanosine in patients with type 2 diabetes mellitus and diabetic patients with coronary heart disease[J].International Journal of Endocrinology and Metabolism,2014,(01):295.[doi:10.3760/cma.j.issn.1673-4157.2014.05.002]
[4]郑佳,肖新华.葡萄糖稳态的中枢调控作用机制
——2014年美国糖尿病协会“杰出科学成就奖”
演讲报告解读[J].国际内分泌代谢杂志,2014,(05):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
Zheng Jia,Xiao Xinhua.The mechanisms of central nervous system in the control of glucose homeostasis--A summary of 2014 ADA "Outstanding Scientific Achievement Award" Lecture[J].International Journal of Endocrinology and Metabolism,2014,(01):305.[doi:10.3760/cma.j.issn.1673-4157.2014.05.004]
[5]唐勤,邵莉.蛋白乙酰化与胰岛素分泌[J].国际内分泌代谢杂志,2014,(05):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
Tang Qin,Shao Li..Protein acetylation and insulin secretion[J].International Journal of Endocrinology and Metabolism,2014,(01):313.[doi:10.3760/cma.j.issn.1673-4157.2014.05.007]
[6]卢婷婷,任思佳,沈捷.人群迁徙对糖尿病患病率的影响及其相关因素[J].国际内分泌代谢杂志,2014,(05):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
Lu Tingting,Ren Sijia,Shen Jie..Impact of migration on prevalence of diabetes and risk factors[J].International Journal of Endocrinology and Metabolism,2014,(01):327.[doi:10.3760/cma.j.issn.1673-4157.2014.05.011]
[7]包薇萍,陈国芳,刘超.DPP-4抑制剂的肾保护作用[J].国际内分泌代谢杂志,2014,(05):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
Bao Weiping,Chen Guofang,Liu Chao..Renal protective effects of dipeptidyl peptidase-4 inhibitors[J].International Journal of Endocrinology and Metabolism,2014,(01):337.[doi:10.3760/cma.j.issn.1673-4157.2014.05.014]
[8]孟庆冬,陶红.巨噬细胞凋亡与糖尿病动脉粥样硬化[J].国际内分泌代谢杂志,2014,(05):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
Meng Qingdong,Tao Hong..Macrophage apoptosis and diabetic atherosclerosis[J].International Journal of Endocrinology and Metabolism,2014,(01):340.[doi:10.3760/cma.j.issn.1673-4157.2014.05.015]
[9]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(01):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[10]吕丹 李晓思 陈树春 王泽普.Betatrophin:糖尿病再生治疗的新希望[J].国际内分泌代谢杂志,2015,(05):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]
Lyu Dan*,Li Xiaosi,Chen Shuchun,et al.Betatrophin:new hope for regeneration therapy of diabetes[J].International Journal of Endocrinology and Metabolism,2015,(01):351.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.016]